Foreword

Peter Naredi
Professor of Surgery, and Chairman, Department of Surgery, Umea University

Peter Naredi is a Professor of Surgery and Chairman of the Department of Surgery at Umea University in Sweden. He specialises in cancer surgery, especially hepatobiliary surgery and melanoma. His main research interests are cisplatin resistance, immunotherapy and treatment of liver and pancreas cancer. Professor Naredi is a Board Member of the European Society of Surgical Oncology (ESSO), with a special interest in educational activities. After defending a thesis in tumour blood flow at Göteborg University, he undertook post-doctorate research at the Cancer Center, University of California, San Diego.

This issue of European Oncological Disease highlights the multifaceted area of oncology. To treat a patient with cancer is not the role of a single physician, but rather a task for a multidisciplinary team. It is the performance of the multidisciplinary team that really matters when it comes to outcome. Outcome is not only a measure of five-year survival – for many patients the possibility of cure or quality of life during remaining lifetime is more important. Cancer treatment therefore has to be individualised; to achieve this the physician must be able to explain treatment options for the patient and also respect the patient’s demands.

From the education and training programme proposed by the European Society of Surgical Oncology (ESSO), it is obvious that a surgeon must not only know how to operate, but also have basic knowledge in many areas of oncology. The skill of the surgical team is of utmost importance for optimal outcome. Radiotherapy or chemotherapy cannot compensate for bad surgery. An oncologist, independent of her or his subspeciality, must know the strengths and weaknesses of different diagnostic and treatment options.

Survival of breast cancer patients has improved over the last few decades and we can expect eight out of 10 patients diagnosed with breast cancer to be cancer survivors. Many minor advances in diagnostic procedures and treatment options are currently being introduced and will further prevent death from breast cancer. The diagnostic procedures identify risk patients, for example triple-negative breast cancer patients. These patients have tumours that are negative for three important drug targets: oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 (HER2). Intraoperative radiotherapy with electrons (ELIOT) offers a single treatment at a high dose and is an interesting option for patients to whom a longer hospital stay may not appeal. The development of new drugs is of benefit for patients with many different tumour types; breast cancer is an illustrative example of how basic scientists, pharmaceutical researchers and clinicians continuously improve treatment alternatives.

In an era where we often recommend not only first- and second-line treatments but also third- and fourth-line alternatives, it is important to remember that the sequentially offered treatment option will likely have less effect and the patient will experience more side effects. Anaemia, malnutrition, nausea and vomiting are all cancer-related complications, but also side effects due to the treatment. It is the responsibility of the multidisciplinary team to use all of the treatment alternatives with great care in order to achieve the best for their patients. This is one of the main reasons for interdisciplinary collaboration in both practice and education. If Europe wants to be a leading continent in oncology, we must continue to work together in organ-based societies and in a European cancer society.

European Oncological Disease would like to thank all contributors to this edition; we hope you find it an interesting and informative read.
BERLIN
GERMANY
15 - 19 APRIL 2008

Emiel Rutgers
Ingrid Kössler
Karin Jöns
Michael Untch

Conference Chair
Conference Co-Chair
Honorary National Representative
Chair National Organising Committee

See you in Berlin in 2008!

Visit us on www.ecco-org.eu